Frazier Life Sciences Management, L.P. Vaxcyte, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 879,405 shares of PCVX stock, worth $75.8 Million. This represents 5.4% of its overall portfolio holdings.
Number of Shares
879,405
Previous 1,039,405
15.39%
Holding current value
$75.8 Million
Previous $78.5 Million
27.92%
% of portfolio
5.4%
Previous 4.63%
Shares
8 transactions
Others Institutions Holding PCVX
# of Institutions
353Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$986 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$942 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$857 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$749 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$422 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.11B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...